Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 19,060 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $13.56, for a total value of $258,453.60. Following the sale, the chief operating officer owned 438,526 shares in the company, valued at approximately $5,946,412.56. This represents a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.83, for a total value of $458,855.03.
- On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.45, for a total value of $275,417.00.
- On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.83, for a total value of $263,599.80.
- On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.37, for a total value of $254,832.20.
- On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total value of $251,210.80.
- On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.41, for a total value of $255,594.60.
- On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07.
- On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total value of $247,017.60.
- On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total value of $457,617.39.
- On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total value of $285,672.80.
Adaptive Biotechnologies Stock Performance
Shares of ADPT stock opened at $14.84 on Thursday. The stock’s fifty day moving average is $15.17 and its 200-day moving average is $15.98. The stock has a market capitalization of $2.29 billion, a PE ratio of -37.10 and a beta of 2.29. Adaptive Biotechnologies Corporation has a 52 week low of $6.77 and a 52 week high of $20.76.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on ADPT shares. Guggenheim upped their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. JPMorgan Chase & Co. upped their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday, February 6th. Finally, Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.25.
View Our Latest Stock Analysis on ADPT
More Adaptive Biotechnologies News
Here are the key news stories impacting Adaptive Biotechnologies this week:
- Positive Sentiment: AAII highlights a sharp intraday rally in ADPT and links the move to the company’s recent quarter-to-quarter momentum, citing earlier-quarter beats in revenue and EPS and strong year-over-year revenue growth as the core catalyst. Why Adaptive Biotechnologies Corporation’s (ADPT) Stock Is Up 10.28%
- Positive Sentiment: The Motley Fool coverage notes revenue jumped roughly mid‑50% year-over-year in the most recent period, a headline that supports the bullish narrative on growth and may be driving buying interest; the piece also flags areas investors should watch (guidance, margins, product adoption). Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%
- Neutral Sentiment: Executives disclosed that many of the recent stock sales were executed under pre‑arranged Rule 10b5‑1 trading plans, which can reduce concerns of opportunistic timing but still represent share supply hitting the market. SEC Form 4 (Example)
- Negative Sentiment: Multiple insider sales by top executives may weigh on sentiment — CEO Chad M. Robins sold blocks on Apr. 6 and Apr. 8 (about 120,595 shares across those filings at prices ~ $14.41–$15.19), and COO Julie Rubinstein sold multiple blocks in early April (roughly 88,000 shares across filings, with trade prices from ~$13.56–$14.83). These transactions reduced each executive’s direct holdings by a few percent. CEO Form 4 COO Form 4
Institutional Investors Weigh In On Adaptive Biotechnologies
A number of hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. raised its position in shares of Adaptive Biotechnologies by 50.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 7,577 shares of the company’s stock worth $123,000 after purchasing an additional 2,550 shares during the period. Corient Private Wealth LLC raised its position in shares of Adaptive Biotechnologies by 3.4% during the fourth quarter. Corient Private Wealth LLC now owns 71,908 shares of the company’s stock worth $1,168,000 after purchasing an additional 2,347 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth about $28,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth about $51,000. Finally, Invesco Ltd. raised its position in shares of Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after purchasing an additional 2,216,595 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Further Reading
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
